Holly Fernandez Lynch, JD, MBE, is Associate Professor of Medical Ethics and Law at the University of Pennsylvania. She pursues conceptual and empirical scholarship regarding clinical research ethics and regulation, access to investigational medicines, and FDA pharmaceutical policy, especially approaches to drug development and early approval pathways for diseases with unmet treatment needs. She is founder and co-chair of the Consortium to Advance Effective Research Ethics Oversight (www.AEREO.org), a collaborative endeavor to define, measure, and improve the quality and effectiveness of institutional review boards and human research protection programs. She was a Greenwall Faculty Scholar from 2019-2022, received the inaugural Baruch A. Brody Bioethics Award in 2020, was elected a fellow of the Hastings Center in 2021, and was selected as a National Academy of Medicine Emerging Leader in Health and Medicine in 2022. She is a board member of Public Responsibility in Medicine & Research (PRIM&R) and board president-elect of the American Society for Law, Medicine, and Ethics. Professor Fernandez Lynch has previously worked as an attorney in private practice, a bioethicist serving NIH’s Division of AIDS, an analyst with President Obama’s Commission for the Study of Bioethical Issues, and executive director of Harvard Law School’s bioethics and health law research program. She earned graduate degrees in law and bioethics at the University of Pennsylvania.
Senior Fellow
Holly Fernandez Lynch, JD, MBE
- Associate Professor, Medical Ethics and Health Policy, Perelman School of Medicine
- Associate Professor, Law, Carey Law School
Related Content
In The Media The Washington Post
How The Supreme Court Has Roiled U.S. Health-care Agencies
Interview
In The Media NPR
A Drug Company Will Stop Selling Lucrative Medicine To Keep a Promise to ALS Patients
Interview
In The Media STAT News
FDA Protocols Originally Intended To Be Extra Conservative Are Now Heralded as Evidence of Mifepristone’s Risk
Interview
LDI News That Caught Your Attention in 2023
Focusing in on Health Care Policy's Most Pressing Issues
In The Media Nature
How a Controversial US Drug Policy Could Be Harming Cancer Patients Worldwide
Interview
In The Media Philadelphia Inquirer
In Philly and Nationwide, Interest Is Rising in Psychedelics To Treat Depression. The FDA Released New Research Guidelines.
Interview
What Does the Inflation Reduction Act Really Mean for Drug Pricing?
A Photo Report from LDI's Health Care Drug Pricing Conference